



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16863-002001	Application No. 10/622,003
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Li-Te Chin	
		Filing Date July 16, 2003	Group Art Unit 1644

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
LW	AA	5,023,252	06/11/2001	Hseih			
	AB	6,190,871	02/20/2001	Ho, et al.			
	AC	6,228,361	05/08/2001	Posner			
	AD	6,261,558	07/17/2001	Barbas, et al.			
	AE	6,309,880	10/30/2001	Chang, et al.			
	AF	6,391,635	05/21/2002	Rodman			
	AG	6,395,275	05/28/2002	Barbas, et al.			
	AH	6,514,496	02/04/2003	Platz, et al.			
	AI	6,592,904	07/15/2003	Platz, et al.			
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							


Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LW	AQ	Breedveld, F.C. (2000). Therapeutic monoclonal antibodies. Lancet 355:735-740.
	AR	Chin, L.T., et al. (1994). Site-directed primary <i>in vitro</i> immunization: production of HIV-1 neutralizing human monoclonal antibodies from seronegative donors. Immunology 81:428-434.
	AS	Chin, L.T., et al. (1995). Mimicking the humoral immune response <i>in vitro</i> results in antigen-specific isotype switching by autologous T helper cells: generation of human HIV-1-neutralizing IgG monoclonal antibodies from naive donors. Eur. J. Immunol. 25:657-663.
	AT	Chin, L.T., et al. (2001). Establishment and evaluation of mouse-human heteromyeloma cell lines obtained by electrofusion for immortalizing human immunoglobulins. J. Biomed. Lab. Sci. 13(4):117-123.
Examiner Signature 		Date Considered 10/19/2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16863-002001	Application No. 10/622,003
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Li-Te Chin	
		Filing Date July 16, 2003	Group Art Unit 1644


Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LW	AU	Co, M.S., <i>et al.</i> (1991). Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. USA 88:2869-2873.
	AV	Demotz, S., <i>et al.</i> (1989). Delineation of several DR-restricted tetanus toxin T cell epitopes. J. Immunol. 142:394-402.
	AW	Dragic, T. (2001). An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. General Virology 82:1807-1814.
	AX	Dueñas, M., <i>et al.</i> (1996). <i>In vitro</i> immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display. Immunology 89(1):1-7.
	AY	Hahn, B.H., <i>et al.</i> (1986). Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 232:1548-1553.
	AZ	Hahn, B.H., <i>et al.</i> (1985). Genomic diversity of the acquired immunodeficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc. Natl. Acad. Sci. USA 82(14):4813-4817.
	AAA	Hill, C.M., <i>et al.</i> (1997). Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol. 71(9):6296-6304.
	ABB	Korber, B.T.M., <i>et al.</i> (Editors). <i>HIV Molecular Immunology</i> 2001. Publisher: Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico. LA-UR 02-2877.
	ACC	Kuhmann, S.E., <i>et al.</i> (2000). Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 74(15):7005-7015.
	ADD	Lee, B., <i>et al.</i> (1999). Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA 96:5215-5220.
	AEE	Modrow, S., <i>et al.</i> (1987). Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J. Virol. 61:570-578.
	AFF	Nermut, M.V., <i>et al.</i> (1993). Further evidence of icosahedral symmetry in human and simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 9:929-938.
	AGG	Ohlin, M., <i>et al.</i> (1989). The effect of leucyl-leucine methyl ester on proliferation and Ig secretion of EBV-transformed human B lymphocytes. Immunology 66:485-490.
	AHH	Ohlin, M., <i>et al.</i> (1992). Epstein-Barr virus-induced transformation of human B lymphocytes: the effect of L-leucyl-L-leucine methyl ester on inhibitory T cell populations. Immunol. Lett. 34:221-228.
	AIJ	Peeters, M. (2000). Recombinant HIV sequences: their role in the global epidemic. Recombinant HIV Sequences, pp. 139-154.
	AJJ	Shiino, T., <i>et al.</i> (2000). A group of V3 sequences from human immunodeficiency virus type 1 subtype E non-syncytium-inducing, CCR5-using variants are resistant to positive selection pressure. J. Virol. 74(3):1069-1078.
	AKK	Staudinger, R., <i>et al.</i> (2003). Evidence for CD4-enhanced signaling through the chemokine receptor CCR5. J Biol. Chem. 278:10389-10392.
↓	ALL	Thomson M.M., <i>et al.</i> (2002). Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect. Dis. 2:461-471.


Examiner Signature 	Date Considered 10/19/2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16863-002001	Application No. 10/622,003
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Li-Te Chin	
		Filing Date July 16, 2003	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LW	AMM	van Dijk, M.A. and van de Winkel, J.G.J. (2001). Human antibodies as next generation therapeutics. <i>Curr. Opin. Chem. Biol.</i> 5(4):368-374.
↓	ANN	Weiner, L.M. (1999). An overview of monoclonal antibody therapy of cancer. <i>Semin. Oncol.</i> 26(4):41-50.
	AOO	Wu, H., <i>et al.</i> (1996). Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. <i>Proc. Natl. Acad. Sci. USA</i> 93:15030-15035.
	APP	Wyatt, R., <i>et al.</i> (1995). Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. <i>J. Virol.</i> 69:5723-5733.
	AQQ	Zafiroopoulos, A., <i>et al.</i> (1997). Induction of antigen-specific isotype switching by <i>in vitro</i> immunization of human naive B lymphocytes. <i>J. Immunol. Methods</i> 200(1-2):181-190.

Examiner Signature 	Date Considered 10/19/2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Sheet 1 of 1

Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16863-002001	Application No. 10/622,003
	Applicant Li-Te Chin			
	Filing Date July 16, 2003		Group Art Unit 1644	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
LW	AD	WO 01/00678 A1	01/04/2001	EPO				
	AE							
	AF							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LW	AG	Dercamp, C., et al. (2002). Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay. Clin Diagn Lab Immunol. 9(2):230-235.
	AH	Kobayashi, Y., et al. (2000). Cell-type specificity of l-leucyl l-leucine methyl ester. Biochem Biophys Res Commun. 272(3):687-690.
	AI	Ohlin, M., et al. (1992). Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope. Clin Exp Immunol. 89(2):290-295.
	AJ	Puhlmann, C.M., and Anderer, F.A. (1995). Optimizing production of human monoclonal IgG antibodies by in vitro-primed human PBMC: influence of CD56+ NK cell depletion. Hybridoma. 14(4):391-396.
	AK	Trujillo, J.R., et al. (1998). Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells. Virology. 246(1):53-62.
V	AL	Zwick, M.B., et al. (2003). A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol. 77(12):6965-6978.

Examiner Signature 	Date Considered 10/19/2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)